BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 36609710)

  • 1. Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs.
    Wanting H; Jian Z; Chaoxin X; Cheng Y; Chengjian Z; Lin Z; Dan C
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5975-5987. PubMed ID: 36609710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
    Chen YC; Chen JH; Hsieh FI
    J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic comparison of anti-angiogenesis efficacy and cardiotoxicity of receptor tyrosine kinase inhibitors in zebrafish model.
    Ma C; Wu Z; Wang X; Huang M; Wei X; Wang W; Qu H; Qiaolongbatu X; Lou Y; Jing L; Fan G
    Toxicol Appl Pharmacol; 2022 Sep; 450():116162. PubMed ID: 35830948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
    Lee N; Lee JL; Lee JY
    Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects.
    Bakri SJ; Lynch J; Howard-Sparks M; Saint-Juste S; Saim S
    PLoS One; 2024; 19(6):e0304782. PubMed ID: 38833447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
    Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
    Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer.
    Kang S; Yeon B; Kim MS; Yoo M; Kim B; Yu YM
    JAMA Netw Open; 2023 Nov; 6(11):e2345977. PubMed ID: 38019511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
    Imano H; Kato R; Ijiri Y; Hayashi T
    Toxicol In Vitro; 2021 Mar; 71():105063. PubMed ID: 33271325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGFR-TKI treatment for radiation-induced brain injury after gamma knife radiosurgery for brain metastases from renal cell carcinomas.
    Noda R; Akabane A; Kawashima M; Uchino K; Tsunoda S; Segawa M; Inoue T
    Jpn J Clin Oncol; 2023 Mar; 53(4):355-364. PubMed ID: 36579769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.
    Goldman A; Bomze D; Dankner R; Fourey D; Boursi B; Arad M; Maor E
    Target Oncol; 2021 Jul; 16(4):471-483. PubMed ID: 33970401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
    Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions.
    Yokoyama H; Shioyama W; Shintani T; Maeda S; Hirobe S; Maeda M; Sakata Y; Fujio Y
    Int Heart J; 2021; 62(6):1297-1304. PubMed ID: 34853223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Je Y; Kaymakcalan MD; Sonpavde G; Choueiri TK
    Br J Cancer; 2015 Jan; 112(2):296-305. PubMed ID: 25349964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.
    Stokes ME; Calvo V; Fujisawa S; Dudgeon C; Huang S; Ballal N; Shen L; Gasparek J; Betzenhauser M; Taylor SJ; Staschke KA; Rigby AC; Mulvihill MJ; Bose N; Lightcap ES; Surguladze D
    Clin Cancer Res; 2023 Dec; 29(23):4870-4882. PubMed ID: 37733811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A subset of VEGFR-TKIs activates AMPK in LKB1-mutant lung cancer.
    Yang L; Zhang Q; Xiong Y; Dang Z; Xiao H; Chen Q; Dai X; Zhang L; Zhu J; Wang D; Li M
    Cancer Sci; 2023 Apr; 114(4):1651-1662. PubMed ID: 36459496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
    Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
    Cells; 2022 May; 11(10):. PubMed ID: 35626731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.